<DOC>
	<DOCNO>NCT02083731</DOCNO>
	<brief_summary>The purpose study evaluate efficacy mesenchymal stem cell ( MSC ) treatment refractory cytomegalovirus ( CMV ) infection allogeneic hematopoietic stem cell transplantation ( allo-HSCT ) .</brief_summary>
	<brief_title>MSC Treatment CMV Infection</brief_title>
	<detailed_description>Viral infection common complication allo-HSCT . With wide use HLA-mismatch , unrelated cord blood donor alternative source hematopoietic stem cell , anti-thymocyte globulin ( ATG ) standard prophylaxis graft versus host disease ( GVHD ) HLA-mismatch unrelated donor transplantation , allo-HSCT recipient increase risk viral infection . Till , CMV remain one important virus cause death recipient allo-HSCT . Approximately 75 % CMV-seropositive recipient develop CMV reactivation , 20-30 % patient develop CMV disease without intervention . Ganciclovir first-line treatment CMV diseases . However , bone marrow suppression , main common side effect , limit utility ganciclovir allo-HSCT recipient . Besides , ganciclovir antiviral agent resistance report 28 % . Since know specific immune response CMV important control reactivation , CMV-specific CTL use prophylaxis treatment CMV viremia several study . However , production CTL require time . Mesenchymal stem cell ( MSC ) form multipotent adult stem cell isolate bone marrow ( BM ) , adipose tissue , cord blood . In vivo experiment show MSCs antimicrobial activity . In trial , use MSCs recipient refractory CMV infection .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<criteria>A patient age 1465 year Refractory CMV infection CMVassociated diseases Subjects ( legally acceptable representative ) must sign informed consent document indicate understand purpose procedure require study willing participate study Any abnormality vital sign ( e.g. , heart rate , respiratory rate , blood pressure ) Patients condition suitable trial ( investigator ' decision )</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>CMV infection</keyword>
	<keyword>Mesenchymal Stem Cells</keyword>
	<keyword>Allogeneic hematopoietic stem cell transplantation</keyword>
</DOC>